Aurinia Pharmaceuticals Inc. Made Big Gain
Thu, Dec 05, 2019 at 05:30 PM
Aurinia Pharmaceuticals Inc. (AUPH:NASDAQ) rocketted at $15, representing a gain of 78.8%. On Wed 04 Dec 19, AUPH:NASDAQ touched a New 2-Week High of $8.39. The stock got featured on our News Catalysts scanner on Thu 05 Dec 19 at 10:45 AM in the 'RECOMMENDATION' category. From Wed 13 Nov 19, the stock recorded 78.57% Up Days and 80.00% Green Days
The share price of the company has been moving sideways in recent weeks.
About Aurinia Pharmaceuticals Inc. (AUPH:NASDAQ)
Aurinia Pharmaceuticals Inc is a clinical stage pharmaceutical company. The Company is engaged in the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis.
Top 10 Gainers:
- Aurinia Pharmaceuticals Inc. (AUPH:NASDAQ), 78.78%
- QuickLogic Corporation (QUIK:NASDAQ), 36.08%
- Proteostasis Therapeutics, Inc. (PTI:NASDAQ), 35.36%
- SecureWorks Corp. (SCWX:NASDAQ), 29.45%
- Iterum Therapeutics plc (ITRM:NASDAQ), 29.09%
- Express, Inc. (EXPR:NYSE), 27.88%
- BIO-key International, Inc. (BKYI:NASDAQ), 27.27%
- Duluth Holdings Inc. (DLTH:NASDAQ), 24.58%
- DermTech, Inc. (DMTK:NASDAQ), 24.21%
- Syndax Pharmaceuticals, Inc. (SNDX:NASDAQ), 21.52%